VAX2012Q: Phase I started

VaxInnate began an open-label, dose-escalation, U.S. Phase I trial to evaluate 4-30 µg of intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's 2011 con...